Lukáš Hrošovský, a 27-year-old from Kysucké Nové Mesto, is battling Friedreich's ataxia, a severe neurodegenerative condition that significantly impairs quality of life and has a low life expectancy. Instead of focusing on his health, he is forced to seek donors and partnerships to finance his treatment, which is exhausting and detracts from his ability to fight his illness.

He has been denied the medication Skyclarys three times by the Slovak healthcare system. This drug, the only one globally that can slow or even halt the progression of his disease, costs about one thousand euros a day. Given the seriousness of his condition, the denial of this treatment feels like a betrayal, especially when he is aware of the significant risks of living without it. Lukáš has become an advocate for patients like him who are in desperate need of financial assistance for life-saving treatments.

The broader implications of his situation raise concerns about healthcare accessibility in Slovakia, highlighting gaps in the support for patients with rare diseases. As Lukáš continues to rely on public fundraising efforts to cover his medication costs, this story shines a light on the challenges and social pressures faced by patients whose treatments are not covered by the state, urging a necessary discussion about healthcare reform and support systems for vulnerable populations.